Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study

被引：0
|
作者：
Jeeyun Lee
Kyung Hae Jung
Young Suk Park
Joong Bae Ahn
Sang Jun Shin
Seock-Ah Im
Do Youn Oh
Dong Bok Shin
Tae Won Kim
Namsu Lee
Jae Ho Byun
Yong Sang Hong
Joon Oh Park
Se Hoon Park
Ho Yeong Lim
Won Ki Kang
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology
[2] Research Institute and Hospital,Oncology, Department of Medicine, Samsung Medical Center
[3] Yonsei University College of Medicine,Center for Colorectal Cancer, National Cancer Center
[4] Seoul National University College of Medicine,Department of Internal Medicine
[5] Gachon University Gil Medical Center,Department of Internal Medicine
[6] University of Ulsan College of Medicine,Division of Hematology and Oncology, Department of Internal Medicine
[7] Soon Chun Hyang University Hospital,Division of Oncology, Department of Medicine, Asan Medical Center
[8] The Catholic University of Korea,Division of Hematology
来源：
Cancer Chemotherapy and Pharmacology | 2009年 / 64卷
关键词：
Statin; Simvastatin; Irinotecan; Cetuximab; Lovastatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：657 / 663
页数：6
相关论文
共 50 条
  • [31] First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: A phase II study
    Tsuji, Yasushi
    Satoh, Taroh
    Tsuji, Akihito
    Muro, Kei
    Yoshida, Motoki
    Nishina, Tomohiro
    Nagase, Michitaka
    Komatsu, Yoshito
    Kato, Takeshi
    Miyata, Yoshinori
    Mizutani, Naoko
    Hashigaki, Satoshi
    Lechuga, Maria Jose
    Denda, Tadamichi
    CANCER SCIENCE, 2012, 103 (08) : 1502 - 1507
  • [32] Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    F Lordick
    B Luber
    S Lorenzen
    S Hegewisch-Becker
    G Folprecht
    E Wöll
    T Decker
    E Endlicher
    N Röthling
    T Schuster
    G Keller
    F Fend
    C Peschel
    British Journal of Cancer, 2010, 102 : 500 - 505
  • [33] Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer
    Aranda, E
    Carrato, A
    Cervantes, A
    Sastre, J
    Gómez, MA
    Abad, A
    Masutti, B
    Ribera, F
    Marcuello, E
    Pronk, L
    Balcells, M
    Díaz-Rubio, E
    ANNALS OF ONCOLOGY, 2004, 15 (04) : 559 - 567
  • [34] Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
    Christos Emmanouilides
    Georgia Sfakiotaki
    Nikolaos Androulakis
    Kostas Kalbakis
    Charalambos Christophylakis
    Antonia Kalykaki
    Lambros Vamvakas
    Athanasios Kotsakis
    Sofia Agelaki
    Eleni Diamandidou
    Nikolaos Touroutoglou
    Adam Chatzidakis
    Vassilis Georgoulias
    Dimitris Mavroudis
    John Souglakos
    BMC Cancer, 7
  • [35] A Phase II Study of Irinotecan, Continuous 5-Fluorouracil, and Leucovorin (FOLFIRI) Combination Chemotherapy for Patients With Recurrent or Metastatic Gastric Cancer Previously Treated With a Fluoropyrimidine-Based Regimen
    Kim, Seok Hyun
    Lee, Gyeong-Won
    Go, Se Il
    Cho, Su Hee
    Kim, Hyun Jin
    Kim, Hun Gu
    Kang, Jung Hun
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (06): : 572 - 576
  • [36] Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study
    Seium, Y
    Stupp, R
    Ruhstaller, T
    Gervaz, P
    Mentha, G
    Philippe, M
    Allal, A
    Trembleau, C
    Bauer, J
    Morant, R
    Roth, AD
    ANNALS OF ONCOLOGY, 2005, 16 (05) : 762 - 766
  • [37] Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma
    Firvida, JL
    Irigoyen, A
    Vázquez-Estévez, S
    Diz, P
    Constenla, M
    Casal-Rubio, J
    Valladares-Ayerbes, M
    Castellanos, J
    Rodríguez, R
    Balcells, M
    CANCER, 2001, 91 (04) : 704 - 711
  • [38] A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
    Gravalos, Cristina
    Salut, Antonieta
    Garcia-Giron, Carlos
    Garcia-Carbonero, Rocio
    Isabel Leon, Ana
    Sevilla, Isabel
    Maurel, Joan
    Esteban, Beatriz
    Garcia-Rico, Eduardo
    Murias, Adolfo
    Cortes-Funes, Hernan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (08) : 606 - 612
  • [39] A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal Cancer
    Lee, Keun-Wook
    Han, Sae-Won
    Kim, Tae Won
    Ahn, Joong Bae
    Baek, Ji Yeon
    Cho, Sang Hee
    Lee, Howard
    Kim, Jin Won
    Kim, Ji-Won
    Kim, Tae-You
    Hong, Yong Sang
    Beom, Seung-Hoon
    Cha, Yongjun
    Choi, Yoonjung
    Kim, Seonhui
    Bang, Yung-Jue
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 590 - 601
  • [40] Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma
    Koutras, A. K.
    Gerolymos, M. K.
    Kontogeorgou, E.
    Iconomou, G.
    Vourli, G.
    Tsiata, E.
    Makatsoris, T.
    Chrysanthopoulos, C.
    Kalofonos, H. P.
    JOURNAL OF CHEMOTHERAPY, 2007, 19 (06) : 724 - 730
12345